The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) is a huge mover today! About 296,594 shares traded hands. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has declined 39.51% since April 8, 2016 and is downtrending. It has underperformed by 45.16% the S&P500.
The move comes after 7 months positive chart setup for the $80.21 million company. It was reported on Nov, 10 by Barchart.com. We have $9.54 PT which if reached, will make NASDAQ:DRNA worth $142.77M more.
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Ratings Coverage
Out of 4 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Dicerna Pharmaceuticals has been the topic of 10 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Tuesday, September 8 by Cowen & Co. The rating was maintained by Chardan Capital Markets on Thursday, June 30 with “Neutral”. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, November 11 report. The firm has “Buy” rating given on Monday, August 10 by Stifel Nicolaus. On Thursday, June 30 the stock rating was maintained by Stifel Nicolaus with “Buy”. The firm has “Neutral” rating given on Monday, August 15 by Chardan Capital Markets. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, May 10.
According to Zacks Investment Research, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 0.76 in 2016 Q2. Its down 0.24, from 1 in 2016Q1. The ratio fall, as 15 funds sold all Dicerna Pharmaceuticals Inc shares owned while 18 reduced positions. 11 funds bought stakes while 14 increased positions. They now own 12.70 million shares or 13.90% less from 14.75 million shares in 2016Q1.
Jpmorgan Chase And has 0% invested in the company for 20,142 shares. Wells Fargo & Co Mn holds 0% or 140 shares in its portfolio. California Pub Employees Retirement System accumulated 41,000 shares or 0% of the stock. Susquehanna Intll Grp Incorporated Limited Liability Partnership accumulated 11,130 shares or 0% of the stock. Fmr Llc has invested 0% of its portfolio in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Renaissance Technologies Ltd Liability reported 75,600 shares or 0% of all its holdings. Lmr Partners Ltd Liability Partnership has 11,757 shares for 0.01% of their US portfolio. Blackrock reported 3,874 shares or 0% of all its holdings. Goldman Sachs Gp has 0% invested in the company for 43,469 shares. The New Jersey-based Blackrock Management Ltd Liability Co has invested 0% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Bourgeon Mngmt Ltd Liability Corporation reported 20,000 shares or 0.04% of all its holdings. Citigroup accumulated 3,569 shares or 0% of the stock. Abingworth Ltd Liability Partnership, a United Kingdom-based fund reported 945,757 shares. The New Jersey-based Jacobs Levy Equity Management has invested 0.01% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Art Advsrs Limited Com has 56,763 shares for 0.01% of their US portfolio.
More news for Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) were recently published by: Businesswire.com, which released: “Dicerna Pharmaceuticals Appoints John â€œJackâ€ Green Interim Chief Financial Officer” on December 15, 2015. Businesswire.com‘s article titled: “Dicerna Pharmaceuticals Submits Investigational New Drug (IND) Application for …” and published on September 02, 2015 is yet another important article.
DRNA Company Profile
Dicerna Pharmaceuticals, Inc., incorporated on October 24, 2006, is a ribonucleic acid (RNA) interference biopharmaceutical company. The Firm operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Firm is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Firm uses its RNAi technology platform to build a pipeline in these therapeutic areas.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.